← Human Trials & Peer-Reviewed Studies
Aromatized Estrogens Amplify Nocturnal Growth Hormone Secretion in Testosterone-Replaced Older Hypogonadal Men.
Plain-language guide to PMID 30032193 (2018): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).
Key Facts
- PMID
- 30032193
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Roelfsema F et al. (6 authors)
- DOI
- 10.1210/jc.2018-00755
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in this randomized controlled trial publication.
To assess the contribution of aromatization of T to spontaneous nocturnal and stimulated GH secretion.
Why It Was Studied
The role of estradiol (E2) in men is less well defined.
Who Took Part
PubMed indexes the participants as adults, middle-aged adults and older adults, men only.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
The gonadotropic axis was clamped with the gonadotropin-releasing hormone antagonist degarelix.
Three groups received T and one group placebo addback.
Two T-replaced groups were treated with anastrozole (an aromatase inhibitor) and either placebo or E2 addback.
What Was Measured
Topics PubMed links to this paper include Administration, Cutaneous, Aging, Anastrozole, Aromatase, Aromatase Inhibitors, Circadian Rhythm and Estradiol.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2018 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- GHRH (Growth Hormone-Releasing Hormone) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.